National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov

Clinical Trials by Cancer Site

Solid Tumor

Solid tumors are masses of abnormal tissue that originate in organs or soft tissues that typically do not include fluid areas and cysts. These tumors can be either benign (noncancerous growths that do not spread to surrounding tissue or organs) or malignant (cancerous tumors that can spread to surrounding tissue and invade other parts of the body). Solid tumors are typically named after the types of cells that compose them. Some examples of solid tumors include: breast cancer, prostate cancer, lung cancer, sarcomas, lymphomas, and carcinomas (lesions that originate in the skin or the lining of organs). Leukemia is not considered a solid tumor because it is a cancer of the blood.

Treatment options vary depending on the type of cancer, stage of the disease, patient's age, and other medical conditions, and should be discussed with the patient's physician.

Solid Tumor Clinical Trials

The Center for Cancer Research (CCR), NCI's largest division doing research on campus, conducts solid tumor clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals to solid tumor clinical trials conducted in Bethesda, Md., through its Clinical Trials Referral Office (formerly the Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for patients with solid tumors. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
Solid Tumor
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses HER-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-HER-2 Gene Engineered Lymphocytes
NCI-09-C-0041

Principal Investigator:Referral Contact:
Steven A. RosenbergLinda Williams
1-866-820-4505
(Toll Free)
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor (Adult)
Phase II
Phase II Study of Metastatic Cancer that Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes
NCI-09-C-0047

Principal Investigator:Referral Contact:
Steven A. RosenbergLinda Williams
1-866-820-4505
(Toll Free)
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination
NCI-08-C-0155

Principal Investigator:Referral Contact:
Steven A. RosenbergLinda Williams
1-866-820-4505
(Toll Free)
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121

Principal Investigator:Referral Contact:
Steven A. RosenbergLinda Williams
1-866-820-4505
(Toll Free)
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases
NCI-07-C-0230

Principal Investigator:Referral Contact:
Deborah CitrinSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov
Phase I
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction
NCI-09-C-0003

Principal Investigator:Referral Contact:
Shivaani KummarLaura D. Otten
301-435-5402301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors
NCI-08-C-0128

Principal Investigator:Referral Contact:
Giuseppe GiacconeJanelle Bingham
301-496-4916301-435-2715
jbingham@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas
NCI-08-C-0091

Principal Investigator:Referral Contact:
Giuseppe GiacconeJanelle Bingham
301-496-4916301-435-2715
jbingham@mail.nih.gov
Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas
NCI-08-C-0087

Principal Investigator:Referral Contact:
Shivaani KummarDeborah Allen
301-435-5402301-402-5640
allendeb@mail.nih.gov
Phase I, Multi-Institutional, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates For Standard Treatment
NCI-08-C-0077

Principal Investigator:Referral Contact:
Raffit HassanBarbara Schuler
301-451-8742301-435-5398
schulerb@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas
NCI-08-C-0030

Principal Investigator:Referral Contact:
Anthony J. MurgoJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
NCI-07-C-0228

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas
NCI-07-C-0203

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas
NCI-07-C-0097

Principal Investigator:Referral Contact:
Anthony J. MurgoJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
NCI-07-C-0047

Principal Investigator:Referral Contact:
Phillip A. DennisHyejeong Root
301-496-0929301-402-0998
roothy@mail.nih.gov
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
NCI-06-C-0221

Principal Investigator:Referral Contact:
James DoroshowJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha
NCI-05-C-0186

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors
NCI-00-C-0121

Principal Investigator:Referral Contact:
John E. JanikGuinevere Chun
301-402-2913301-451-7868
gchun@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer
NCI-07-C-0101

Principal Investigator:Referral Contact:
Peter ChoykeYolanda McKinney
301-451-4220301-443-1718
ymckinney@mail.nih.gov
No Phase
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111

Principal Investigator:Referral Contact:
Deborah CitrinSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCI-97-C-0147

Principal Investigator:Referral Contact:
W. Marston Linehan
301-496-6353



  
Trial and Protocol Number
Solid Tumor (Childhood)
Phase I
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714)
NCI-08-C-0179

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents With Advanced Solid Tumors
NCI-08-C-0010

Principal Investigator:Referral Contact:
Frank BalisPediatric Oncology
301-496-00851-877-624-4878
(Toll free)

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)

A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study)
NCI-07-C-0166

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors
NCI-07-C-0040

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)



  
Trial and Protocol Number
Pediatric Cancers
Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias
NCI-06-C-0233

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)

Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia
NCI-06-C-0152

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)



Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure